BeiGene ANZ adopts BeOne Medicines in major rebrand

Over the past few years, a wave of rebranding has swept the pharma and biotech sector. In this context, BeiGene AUS has officially rebranded as BeOne Medicines in Australia and New Zealand. The China-origin company has also relocated its legal headquarters from the Cayman Islands to Basel, Switzerland – joining global pharma leaders such as Roche and Novartis.

“Australia and New Zealand are priority locations for BeOne’s global clinical development efforts, thanks to their established research networks and internationally respected trial infrastructure,” said Adam Roach, SVP and Head of Japan and Asia Pacific, BeOne. “Our work across both countries contributes meaningfully to BeOne’s mission to improve outcomes for people living with cancer worldwide.”

The new name carries deep significance: the “Be” represents the fundamental goal of any patient with cancer to be free of disease, while “One” emphasises the power of unity, bringing together patients, caregivers, scientists, healthcare providers, governments, and industry in a shared mission to eliminate cancer.

BeOne’s Australian and New Zealand footprint now totals 266 employees, with more than 80% dedicated to clinical operations. This focus highlights the region’s critical role in driving BeOne’s global research engine and its commitment to clinical excellence. Local trial infrastructure, trusted research partnerships, and a highly skilled operational team underpin the company’s push to accelerate oncology innovation.

“The company’s transition to Switzerland marks an important milestone for our business- one that enhances our global capabilities and positions BeOne to scale our innovation even more effectively across countries,” Roach added.

Since its inception in 2010, BeOne has cultivated a differentiated and scalable model for drug discovery, development, and patient access. With integrated R&D and manufacturing capabilities, a global portfolio spanning haematology and solid tumours, and over 11,000 employees across six continents, the company is strategically positioned to advance innovation and improve affordability in cancer care.

“BeOne is more than a new name – it’s a signal of who we are and what we stand for: a company uniting people, science, and systems around the world in the shared mission to beat cancer,” said John V. Oyler, Co-Founder, Chairman, and CEO of BeOne. “This next chapter will help us deliver on our vision to radically improve access to high-quality cancer therapies for patients in every corner of the world.”

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.